<DOC>
	<DOCNO>NCT02573012</DOCNO>
	<brief_summary>This Phase IIIb/IV , two-arm , randomize , double-blind , placebo-controlled , parallel-group , international , multicenter trial compare change disease activity ( assessed Disease Activity Score 28 joint [ DAS28 ] erythrocyte sedimentation rate [ ESR ] ) randomization Week 24 post-randomization , participant stable low disease activity [ LDA ] ( DAS28 ESR score less equal [ &lt; = ] 3.2 ) receive tocilizumab , randomize either continue taper prednisone double-blinded fashion .</brief_summary>
	<brief_title>Study Compare Efficacy Tocilizumab With Without Glucocorticoid Discontinuation Rheumatoid Arthritis Participants</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Tocilizumabexperienced participant : Comply requirement study protocol ( include treatment outpatient basis ) Rheumatoid arthritis ( RA ) great equal ( &gt; = ) 6 month duration diagnose accord revised 1987 American College Rheumatology ( ACR ) criterion 2010 ACR / European League Against Rheumatism ( EULAR ) criterion Have receive tocilizumab either subcutaneous ( 162 milligram [ mg ] week ) intravenously ( 8 milligram per kilogram [ mg/kg ] every 4 week ) treatment RA least 24 week prior randomization Have receive 5 15 milligram per day [ mg/day ] glucocorticoid ( prednisone equivalent ) treatment RA least 20 week prior screen Currently receive 5 mg/day prednisone Have attain maintain LDA ( DAS28 ESR score &lt; =3.2 ) remission ( DAS28 ESR score less [ &lt; ] 2.6 ) least 4 week prior randomization Tocilizumabnaïve participant : Comply requirement study protocol ( include treatment outpatient basis ) RA &gt; =6 month duration diagnose accord revised 1987 ACR criterion 2010 ACR / EULAR criterion Have active RA ( define DAS28 ESR score great [ &gt; ] 3.2 ) Are consider investigator inadequate responder conventional synthetic diseasemodifying antirheumatic drug ( csDMARDs ) biologic diseasemodifying antirheumatic drug ( bDMARDs ) Are receive 5 15 mg/day prednisone ( equivalent ) treatment RA General Major surgery ( include joint surgery ) within 8 week prior screen , plan major surgery study 6 month randomization Pregnant woman nurse ( breastfeed ) mother In female childbearing potential , positive serum pregnancy test screening Females childbearing potential unwilling unable use reliable mean contraception ( example , physical barrier [ participant partner ] , contraceptive pill patch , spermicide barrier , intrauterine device ) study treatment minimum 3 month last dose tocilizumab Body weight &gt; =150 kilogram ( kg ) Lack peripheral venous access Diseaserelated RA functional Class 4 , define ACR Classification Functional Status Rheumatoid Arthritis Rheumatic autoimmune disease RA , include systemic lupus erythematosus , mixed connective tissue disease , scleroderma , polymyositis , significant systemic involvement secondary RA ( example , vasculitis , pulmonary fibrosis , Felty syndrome ) . Secondary Sjögren syndrome RA may allow per discretion investigator Diagnosed juvenile idiopathic arthritis juvenile RA and/or RA age 16 year Prior current inflammatory joint disease RA ( example , gout , Lyme disease , seronegative spondyloarthropathy , include reactive arthritis , psoriatic arthritis , arthropathy inflammatory bowel disease ) , prior current joint infection Previous history primary secondary adrenal insufficiency Previous Concomitant Prohibited Therapy Treatment investigational agent within 4 week ( 5 halflives investigational drug , whichever long ) screen Previous treatment celldepleting therapy , include investigational agent approve therapy ( example , CAMPATH , antiCD4 , antiCD5 , antiCD3 , antiCD19 , antiCD20 ) Treatment intravenous gamma globulin , plasmapheresis Prosorba column within 6 month screen Intraarticular ( IA ) parenteral glucocorticoid treatment RA within 4 week prior screen Previous treatment glucocorticoid condition RA , dose formulation use continuously &gt; 1 week , last 1 year prior screen . Topical glucocorticoid cream ointment treatment skin condition ( example eczema ) allow Immunization live/attenuated vaccine within 30 day prior screen . Participants must agree take live attenuate vaccine ( include seasonal nasal flu vaccine , varicella vaccine shingle chickenpox , vaccine measles , mumps rubella without varicella [ MMR MMRV ] , oral polio vaccine vaccine yellow fever ) , within 30 day Screening Visit , throughout duration trial 60 day follow last dose study drug Any previous treatment alkylating agent chlorambucil total lymphoid irradiation Laboratory Exclusion Criteria Inadequate haematological , renal liver function Positive hepatitis B surface antigen hepatitis C antibody Previous Concomitant Conditions History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody Evidence current serious uncontrolled cardiovascular ( include uncontrolled hyperlipidemia ) , nervous system , pulmonary ( include obstructive pulmonary disease ) , renal , hepatic , endocrine ( include uncontrolled diabetes mellitus ) gastrointestinal ( GI ) disease Current liver disease determine investigator History diverticulitis , peptic ulcer disease , diverticulosis require antibiotic treatment , chronic ulcerative low GI disease Crohn 's disease , ulcerative colitis , symptomatic low gastrointestinal condition might predispose perforation Known active current history recurrent bacterial , viral , fungal , mycobacterial , opportunistic infection ( include , limited , tuberculosis [ TB ] atypical mycobacterial disease , hepatitis B C , EpsteinBarr virus , cytomegalovirus herpes zoster , exclude fungal infection nail bed ) Neuropathies condition might interfere pain evaluation unless related primary disease investigation Any major episode infection require hospitalization treatment intravenous antibiotic within 4 week screen oral antibiotic within 2 week prior screen Active TB require treatment within previous 3 year ( participant previously treat TB recurrence within 3 year permit ) . All Track tocilizumabnaïve participant must screen latent TB positive , treat follow local practice guideline prior initiate tocilizumab History currently active , primary secondary immunodeficiency Evidence active malignant disease , malignancy diagnose within previous 10 year ( include haematological malignancy solid tumour , except basal squamous cell carcinoma skin carcinoma situ cervix uterus excise cure ) , breast cancer diagnose within previous 20 year History alcohol , drug chemical abuse within 1 year prior screen Preexisting central nervous system ( CNS ) demyelination seizure disorder Any medical psychological condition opinion principal investigator would interfere safe completion trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>